JSM 2015 Preliminary Program

Online Program Home
My Program

Abstract Details

Activity Number: 260
Type: Contributed
Date/Time: Monday, August 10, 2015 : 2:00 PM to 3:50 PM
Sponsor: Biopharmaceutical Section
Abstract #316705
Title: Improving Power for Biomarker Detection with Joint Modeling of Multiple Endpoints in Early-Phase Clinical Trials
Author(s): Qianying Liu* and Glen Laird and Wei Zheng
Companies: Sanofi and Sanofi and Sanofi
Keywords: biomarker ; tumor growth model ; treatment response ; progression-free survival
Abstract:

Biomarkers play an important role in identifying subgroup of patients who are most likely to receive benefit from investigational treatments. In early-stage clinical trials, it is challenging to identify biomarkers due to limited sample size and short study duration. In oncology, multiple surrogate endpoints have been considered to evaluate treatment effects and detect biomarkers, for example, treatment response and progression-free survival (PFS). In this work, we propose to use weighted sum of test statistics for multiple endpoints to improve the power for detecting biomarker-treatment interactions. We derived the optimal weight for combining these statistics. With simulations of tumor growth data, we showed that the proposed method outperforms statistical methods using single endpoint. In addition, we showed that power is robust to misspecifications of parameters, such as the correlation between test statistics for different endpoints.


Authors who are presenting talks have a * after their name.

Back to the full JSM 2015 program





For program information, contact the JSM Registration Department or phone (888) 231-3473.

For Professional Development information, contact the Education Department.

The views expressed here are those of the individual authors and not necessarily those of the JSM sponsors, their officers, or their staff.

2015 JSM Online Program Home